Curated Information
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage PhosphoSitePlus® v6.5.9.3
Powered by Cell Signaling Technology
Home > Curated Information Page > PubMed Id: 28506461
Jaco I, et al. (2017) MK2 Phosphorylates RIPK1 to Prevent TNF-Induced Cell Death. Mol Cell 66, 698-710.e5 28506461
This page summarizes selected information from the record referenced above and curated into PhosphoSitePlus®, a comprehensive online resource for the study of protein post-translational modifications (NAR, 2015, 43:D512-20). To learn more about the scope of PhosphoSitePlus®, click here.
Click on the protein name to open the protein page, and on the RSD number to open the site page.
Download

S320-p - RIPK1 (human)
Modsite: AVVkRMQsLQLdCVA SwissProt Entrez-Gene
Orthologous residues
RIPK1 (human): S320‑p, RIPK1 iso2 (human): S274‑p, RIPK1 (mouse): S321‑p, RIPK1 (rat): S320‑p
Characterization
Methods used to characterize site in vivo immunoprecipitation, mutation of modification site, phospho-antibody, western blotting
Disease tissue studied:  breast cancer, breast adenocarcinoma, breast cancer, triple negative
Relevant cell lines - cell types - tissues:  293 (epithelial), macrophage-bone marrow, MDA-MB-231 (breast cell), MDA-MB-468 (breast cell), MEF (fibroblast)
Cellular systems studied:  cell lines, primary cells
Species studied:  human, mouse
Enzymes shown to modify site in vitro
Type Enzyme
KINASE MAPKAPK2 (human)
Upstream Regulation
Potential in vivo enzymes for site: 
Type Enzyme Evidence Notes
KINASE MAPKAPK2 (human) genetic knockout/knockin of upstream enzyme, phospho-antibody, modification site within consensus motif
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
TNF increase
PF3644022 TNF inhibit treatment-induced increase
Downstream Regulation
Effect of modification (function):  molecular association, regulation
Effect of modification (process):  apoptosis, inhibited
Modification regulates interactions with: 
Interacting molecule Interacting domains Effect Consequences (function) Consequences (process) Detection assays
FADD (human) Disrupts co-immunoprecipitation

S321-p - RIPK1 (mouse)
Modsite: PVLQRMFsLQHDCVP SwissProt Entrez-Gene
Orthologous residues
RIPK1 (human): S320‑p, RIPK1 iso2 (human): S274‑p, RIPK1 (mouse): S321‑p, RIPK1 (rat): S320‑p
Characterization
Methods used to characterize site in vivo immunoprecipitation, mutation of modification site, phospho-antibody, western blotting
Disease tissue studied:  breast cancer, breast adenocarcinoma, breast cancer, triple negative
Relevant cell lines - cell types - tissues:  293 (epithelial), macrophage-bone marrow, MDA-MB-231 (breast cell), MDA-MB-468 (breast cell), MEF (fibroblast)
Cellular systems studied:  cell lines, primary cells
Species studied:  human, mouse
Enzymes shown to modify site in vitro
Type Enzyme
KINASE MAPKAPK2 (human)
Upstream Regulation
Potential in vivo enzymes for site: 
Type Enzyme Evidence Notes
KINASE MAPKAPK2 (human) genetic knockout/knockin of upstream enzyme, phospho-antibody, modification site within consensus motif
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
TNF increase
PF3644022 TNF inhibit treatment-induced increase
Downstream Regulation
Effect of modification (function):  molecular association, regulation
Effect of modification (process):  apoptosis, inhibited
Modification regulates interactions with: 
Interacting molecule Interacting domains Effect Consequences (function) Consequences (process) Detection assays
FADD (human) Disrupts co-immunoprecipitation
FADD (mouse) Disrupts co-immunoprecipitation